


SCIENTIFIC PROGRAM



EST

9:00 AM



CET

15:00

Friday, July 9

July 9-10, 2021

Introduction by Chairman **A Mebazaa** (Paris, FR)

9:05 AM

15:05

SESSION 1: TRIALS DURING COVID-19 PANDEMICIA

Co-Chairs: **W Self** (Nashville, US) & **T Chen** (New York City, US)

COVID vs non-COVID: how different is it in designing trial?: **A De Jong** (Montpellier, FR) - 10 minutes

Platform trial iSPY: **N Meyer** (Philadelphia, US) - 10 minutes

Trial Efficiency in a Pandemic - Lessons Learned: **J Casey** (Nashville, US) - 10 minutes

The Lancet Editor's perspective: **S Spencer** (The Lancet, UK) - 10 minutes

Industry perspective: **E Wagner** (Constant Therapeutics, US) - 10 minutes

NIH perspective: **Y Rosenberg** (NHLBI, US) - 10 minutes

FDA perspective: **A Farb** (FDA, USA) - 10 minutes

Panel discussion: 30 minutes

10:45 AM

16:45

Break

11:00 AM

17:00

SESSION 2: NOVELTIES IN TRIALS IN SEPTIC SHOCK

Co-Chairs: **C Dos Santos** (Toronto, CA) & **A Mebazaa** (Paris, FR)

REVIVAL: **P Pickkers** (Nijmegen, NL) - 10 minutes

ASTONISH: **B François** (Limoges, FR) - 10 minutes

ADRENOSS-2: **A Mebazaa** (Paris, FR) - 10 minutes

Encourage 1 & 2: **P-F Laterre** (Brussels, BE) - 10 minutes

i-Micro: **F Dépret** (Paris, FR) - 10 minutes

Platelets in septic shock: are we ready for a trial?: **V Léopold** (Paris, FR) - 5 minutes

EMA perspective: **M Kostubriec** (EMA, PL) - 5 minutes


Panel discussion: 30 minutes

12:30 PM

18:30

Adjourn

SCIENTIFIC PROGRAM



July 9-10, 2021



Saturday, July 10

9:00 AM 15:00 Introduction by Chairman A Mebazaa (Paris, FR)

9:05 AM 15:05 **SESSION 3: CARIOGENIC SHOCK: DEFINITION AND FUTURE**
Co-Chairs: A Farb (FDA, US) & S Price (London, UK)

Definition of Refractory Shock: M Gilard (Brest, FR) & W O'Neill (Detroit, US) - 10 minutes
SEISMIC: M Metra (Brescia, IT) - 5 minutes
STRONG-HF: G Cotter (Momentum Research, US) - 5 minutes
ANCHOR: A Combes (Paris, FR) - 5 minutes
US Network: M Krucoff (Durham, US) - 5 minutes
Current and upcoming US trials: W O'Neill (Detroit, US) - 5 minutes
Consent and inclusion: A Mebazaa (Paris, FR) - 5 minutes
Industry perspective: P Lombardi (Getinge, USA) - 5 minutes
FDA perspective: M Moscucci (FDA, US) - 5 minutes
EMA perspective: M Kostubriec (EMA, PL) 5 minutes
Patient perspective: R Monroe (Martinsburg, US) - 5 minutes
Panel discussion: 30 minutes

10:35 AM 16:35 Break

10:50 AM 16:50 **SESSION 4: ARDS: UNIVERSAL DEFINITION FOR SUCCESSFUL TRIALS**
Co-Chairs: E Grainger (Lancet Respiratory Medicine), S Jaber (Intensive Care Medicine)
& N Aggarwal (NHLBI, US)

Universal definition of ARDS: are we ready for prime time?: M Matthay (San Francisco, US) - 10 minutes
Machine Learning and imaging: N Lassau (Paris, FR) - 10 minutes
Phenotypes: clinical, physiologic & biologic: P Sinha (San Francisco, US) - 10 minutes
Key to design best ARDS trial: L Ware (Nashville, US) - 10 minutes
ECMO is here to stay: G LeBreton (Paris, FR) - 10 minutes
The best design is mine: ASTER trial: A Fowler (Richmond, US) - 5 minutes
Biologic effect of MSCs in ARDS: first results: K Wick (San Francisco, US) - 5 minutes
My trial assessing MCS: P-F Laterre (Brussels, BE) - 5 minutes
Inhaled steroids and beta-agonists in ED: J Levitt (Stanford, US) - 5 minutes
Patient perspective: E Rubin (Northbrook, US) - 5 minutes
NIH perspective: L Reineck (NHLBI, US) - 5 minutes
FDA perspective: 5 minutes
EMA perspective: M Kostrubiec (EMA, PL) - 5 minutes
Panel discussion: 20 minutes

12:50 PM 18:50 Break

1:00 PM 19:00 Key messages: L Brochard (Toronto, CA) & M Antonelli (Rome, IT) - 10 minutes
1:10 PM 19:10 Closing words: A Mebazaa (Paris, FR) - 5 minutes
1:15 PM 19:15 Adjourn